AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 362207 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 children requiring only non-corticosteroid medication)
Number of subjects: 20
Study 30502903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 27
Study 30502903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 28557642 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 26
Study 28557642 — intervention group
Group type: COMPARATOR
Intervention: 940 +/‐ 15‐nm diode laser
Number of subjects: 26
Study 28557642 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 26
Study 28557642 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing + Er,Cr:YSGG laser
Number of subjects: 26
Study 28557642 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing + 940 +/‐ 15‐nm diode laser
Number of subjects: 26
Study 28557642 — intervention group
Group type: COMPARATOR
Intervention: Only scaling and root planing
Number of subjects: 26
Study 25512461 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus TH-302 240 mg/m2 (G+T240)
Number of subjects: 214
Study 25512461 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus TH-302 340 mg/m2 (G+T340)
Number of subjects: 214
Study 25512461 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1,000 mg/m2)
Number of subjects: 214
Study 25512461 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 214
Study 23334588 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol Camel crush for 15 days followed by non-menthol Camel crush for 15 days
Number of subjects: 32
Study 23334588 — intervention group
Group type: COMPARATOR
Intervention: Own brand cigarette across all periods
Number of subjects: 32
Study 21667021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μM all-trans retinoic acid (atRA) for 4 days
Number of subjects: 9
Study 21667021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μM 4-hydroxy-phenylretinamide (4-HPR) for 4 days
Number of subjects: 9
Study 21667021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μM 9-cis retinoic acid (9cRA) for 4 days
Number of subjects: 9
Study 21667021 — intervention group
Group type: EXPERIMENTAL
Intervention: siRNA suppression of RARβ5 in BCA-2 cells
Number of subjects: 9
Study 21667021 — intervention group
Group type: EXPERIMENTAL
Intervention: atRA treatment
Number of subjects: 9
Study 19488979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxazolam (test, Eurofarma Lab. Ltda)
Number of subjects: 0
Study 19488979 — intervention group
Group type: COMPARATOR
Intervention: Olcadil (reference, Novartis Biociências S/A)
Number of subjects: 0
Study 17130503 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 or 300 mg once daily)
Number of subjects: 269
Study 17130503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 15142885 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered red blood cell transfusions
Number of subjects: 1051
Study 15142885 — intervention group
Group type: COMPARATOR
Intervention: Non-filtered red blood cell transfusions
Number of subjects: 1051
Study 11240108 — intervention group
Group type: COMPARATOR
Intervention: Normal elderly subjects
Number of subjects: 51
Study 11240108 — intervention group
Group type: COMPARATOR
Intervention: PD patients
Number of subjects: 51
Study 11240108 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal young subjects
Number of subjects: 51
Study 9151069 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% palatinose
Number of subjects: 15
Study 9151069 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5% palatinose + 12.5% xylitol
Number of subjects: 15
Study 9151069 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% xylitol
Number of subjects: 15
Study 9151069 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose rinse
Number of subjects: 15
Study 9151069 — intervention group
Group type: EXPERIMENTAL
Intervention: xylitol period
Number of subjects: 15
Study 9151069 — intervention group
Group type: EXPERIMENTAL
Intervention: xylitol
Number of subjects: 15
Study 9151069 — intervention group
Group type: COMPARATOR
Intervention: Control (no mouthrinses)
Number of subjects: 15
Study 7855186 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 5 weeks after a 1-week wash-out and 1-week placebo period.
Number of subjects: 16
Study 3324956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 66
Study 3324956 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 66
Study 29512517 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid functional with a uniform parameter
Number of subjects: 0
Study 25955823 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic body awareness therapy (BAT)
Number of subjects: 113
Study 25955823 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy (ET)
Number of subjects: 113
Study 23645162 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT-E
Number of subjects: 8
Study 23645162 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT-V
Number of subjects: 8
Study 23645162 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT
Number of subjects: 8
Study 23645162 — intervention group
Group type: EXPERIMENTAL
Intervention: Elekta machine (IMRT and VMAT)
Number of subjects: 8
Study 23645162 — intervention group
Group type: COMPARATOR
Intervention: IMRT-E and IMRT-V
Number of subjects: 8
Study 23645162 — intervention group
Group type: COMPARATOR
Intervention: VMAT-E and VMAT-V
Number of subjects: 8
Study 23521461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injection of contrast agent mixed with 2% mepivacaine
Number of subjects: 120
Study 23521461 — intervention group
Group type: COMPARATOR
Intervention: Control group received contrast agent only
Number of subjects: 120
Study 20876826 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the Drug Burden Index (DBI) provided to general practitioners (GPs) via a letter and phone call, prompting cessation or dose reduction of anticholinergic and sedative medications.
Number of subjects: 115
Study 20876826 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 115
Study 18836789 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h theory‐based behavioral HIV‐alcohol risk‐reduction intervention
Number of subjects: 353
Study 18836789 — intervention group
Group type: COMPARATOR
Intervention: 1‐h HIV‐alcohol information/education control group
Number of subjects: 353
Study 16622436 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI gastrazole
Number of subjects: 116
Study 16622436 — intervention group
Group type: COMPARATOR
Intervention: PVI placebo
Number of subjects: 116
Study 16622436 — intervention group
Group type: COMPARATOR
Intervention: PVI fluorouracil (5‐FU)
Number of subjects: 116
Study 12809173 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 (2 microg/kg iv)
Number of subjects: 10
Study 12809173 — intervention group
Group type: COMPARATOR
Intervention: DDAVP (10 microg iv)
Number of subjects: 10
Study 12113193 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation treatment for ductal carcinoma in situ (DCIS)
Number of subjects: 0
Study 12113193 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter radiation schedules
Number of subjects: 0
Study 12113193 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation
Number of subjects: 0
Study 12113193 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation for systemic metastases from breast cancer
Number of subjects: 0
Study 9717655 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with collagen implant (DSCI)
Number of subjects: 46
Study 9717655 — intervention group
Group type: COMPARATOR
Intervention: Standard trabeculectomy
Number of subjects: 46
Study 7993148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (at least 95% adherence)
Number of subjects: 22071
Study 7993148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (taking < 50% of study tablets)
Number of subjects: 22071
Study 7993148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (better adherence)
Number of subjects: 22071
Study 3180636 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide gel, 8 gm t.i.d.
Number of subjects: 10
Study 3180636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30883054 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cardioversion
Number of subjects: 427
Study 30883054 — intervention group
Group type: COMPARATOR
Intervention: Delayed cardioversion
Number of subjects: 427
Study 29390461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle acupuncture
Number of subjects: 90
Study 29390461 — intervention group
Group type: COMPARATOR
Intervention: Traditional needle manipulation
Number of subjects: 90
Study 29390461 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 90
Study 25840298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralase iFS 150 kHz femtosecond laser
Number of subjects: 61
Study 25840298 — intervention group
Group type: COMPARATOR
Intervention: Intralase FS 60 kHz femtosecond laser
Number of subjects: 61
Study 23374986 — intervention group
Group type: COMPARATOR
Intervention: Biventricular (BV) repair
Number of subjects: 102
Study 23374986 — intervention group
Group type: COMPARATOR
Intervention: 1.5-ventricle (1.5V) repair
Number of subjects: 102
Study 23374986 — intervention group
Group type: COMPARATOR
Intervention: Univentricular (UV) repair
Number of subjects: 102
Study 23374986 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (BV, UV, 1.5V)
Number of subjects: 102
Study 21127429 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated BP measurement
Number of subjects: 44
Study 21127429 — intervention group
Group type: COMPARATOR
Intervention: Manual BP measurement
Number of subjects: 44
Study 19270030 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Scored PSC administration
Number of subjects: 174
Study 19270030 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-Scored PSC administration
Number of subjects: 174
Study 19270030 — intervention group
Group type: COMPARATOR
Intervention: Typical medical care control
Number of subjects: 174
Study 17097958 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (group 1)
Number of subjects: 58
Study 17097958 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment (group 0)
Number of subjects: 58
Study 15271745 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSB) with 10 mL of 0.25% bupivacaine
Number of subjects: 120
Study 15271745 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular local anesthetic (IA) with 20 mL of 0.25% bupivacaine
Number of subjects: 120
Study 15271745 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB) with 20 mL of 0.25% bupivacaine
Number of subjects: 120
Study 15271745 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 11720825 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy (neoadjuvant chemotherapy, Patey mastectomy, postoperative radiotherapy and adjuvant hormone therapy)
Number of subjects: 108
Study 11720825 — intervention group
Group type: COMPARATOR
Intervention: Initial hormone therapy
Number of subjects: 108
Study 11720825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapy groups
Number of subjects: 108
Study 9035396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap detection for 50-Hz-wide markers in 0-dB/Hz noise
Number of subjects: 50
Study 9035396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap detection for 1000-Hz-wide markers in 0-dB/Hz noise
Number of subjects: 50
Study 9035396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap detection for 50-Hz-wide markers in 40-dB/Hz noise
Number of subjects: 50
Study 9035396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap detection for 50-Hz-wide markers at equal SL's in 0-dB/Hz and 55-dB/Hz noise
Number of subjects: 50
Study 9035396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap detection for markers presented at similar SLs across background noise levels
Number of subjects: 50
Study 9035396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap detection related to marker-to-noise ratio
Number of subjects: 50
Study 7895951 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamping (plasma glucose approximately 15 mmol/l) with somatostatin suppression of insulin secretion
Number of subjects: 13
Study 7895951 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycaemic clamping (plasma glucose approximately 5 mmol/l) with somatostatin infusion
Number of subjects: 13
Study 3312825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg twice daily)
Number of subjects: 173
Study 31348308 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia + epidural anesthesia + Narcotrend D2
Number of subjects: 120
Study 31348308 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia + Narcotrend D1
Number of subjects: 120
Study 31348308 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia + Narcotrend D2
Number of subjects: 120
Study 31348308 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia + epidural anesthesia + Narcotrend D1
Number of subjects: 120
Study 31348308 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 120
Study 31348308 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia at Narcotrend D2 depth
Number of subjects: 120
Study 28603901 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration (50 mg topical gel)
Number of subjects: 103
Study 28603901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 28603901 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 103
Study 25078052 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient misoprostol administration (800 mcg intra-vaginally, eight hourly, maximum of three doses)
Number of subjects: 154
Study 25078052 — intervention group
Group type: COMPARATOR
Intervention: Inpatient misoprostol administration (800 mcg intra-vaginally, eight hourly, maximum of three doses)
Number of subjects: 154
Study 25078052 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient misoprostol administration
Number of subjects: 154
Study 25078052 — intervention group
Group type: COMPARATOR
Intervention: Inpatient misoprostol administration
Number of subjects: 154
Study 25078052 — intervention group
Group type: EXPERIMENTAL
Intervention: Both outpatient and inpatient misoprostol administration
Number of subjects: 154
Study 24280479 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Intervention (MI)
Number of subjects: 100
Study 24280479 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 21861719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon 1,200 mg/day
Number of subjects: 59
Study 21861719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19332203 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-antiplatelet therapy with cilostazol, aspirin, and clopidogrel
Number of subjects: 1212
Study 19332203 — intervention group
Group type: COMPARATOR
Intervention: Dual-antiplatelet treatment with aspirin and clopidogrel
Number of subjects: 1212
Study 16783519 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study 16783519 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute schizophrenia
Number of subjects: 0
Study 16783519 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia
Number of subjects: 0
Study 15367413 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² followed by epirubicin 80 mg/m² (group A)
Number of subjects: 327
Study 15367413 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel followed by carboplatin at an AUC of 6 mg x min/ml (group B)
Number of subjects: 327
Study 15367413 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel followed by carboplatin (group B)
Number of subjects: 327
Study 15367413 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel followed by epirubicin (group A)
Number of subjects: 327
Study 15367413 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 327
Study 15367413 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment and cost analysis
Number of subjects: 327
Study 11748315 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (20 Hz)
Number of subjects: 23
Study 11748315 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency rTMS (5 Hz)
Number of subjects: 23
Study 9195203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous dexamethasone (1 mg/m2)
Number of subjects: 14
Study 9195203 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 14
Study 9195203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral dexamethasone (2 mg)
Number of subjects: 14
Study 9195203 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 14
Study 9195203 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-releasing hormone
Number of subjects: 14
Study 8285649 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) - 400 kcal/day, only lean meat, fish, or fowl allowed
Number of subjects: 93
Study 8285649 — intervention group
Group type: COMPARATOR
Intervention: Balanced Low Calorie Diet (LCD) - 1000-1200 kcal/day, all foods allowed in moderation
Number of subjects: 93
Study 3557731 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg labetalol daily for eight weeks
Number of subjects: 21
Study 3557731 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg labetalol daily for eight weeks
Number of subjects: 21
Study 3557731 — intervention group
Group type: COMPARATOR
Intervention: Placebo for one week
Number of subjects: 21
Study 29753994 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily calorie restriction diet (22% daily reduction in energy needs)
Number of subjects: 36
Study 29753994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction diet (75% reduction in energy needs, 2 days/week; 0% reduction, 5 days/week)
Number of subjects: 36
Study 29753994 — intervention group
Group type: COMPARATOR
Intervention: Weight-stable diet (0% reduction in energy needs, 7 days/week)
Number of subjects: 36
Study 29753994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both calorie restriction diets (daily and intermittent)
Number of subjects: 36
Study 27769310 — intervention group
Group type: EXPERIMENTAL
Intervention: CueS wristband providing 'live' feedback towards pre-set movement goals during a 4-week upper limb therapy programme.
Number of subjects: 60
Study 27769310 — intervention group
Group type: COMPARATOR
Intervention: Sham CueS wristband that monitors upper limb activity but provides no feedback during a 4-week upper limb therapy programme.
Number of subjects: 60
Study 25539929 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) 3.0 pmol·kg(‐1)·min(‐1) during a continuous infusion lasting for 4 h
Number of subjects: 10
Study 25539929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23033237 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop therapy
Number of subjects: 10
Study 23033237 — intervention group
Group type: COMPARATOR
Intervention: Open-loop therapy
Number of subjects: 10
Study 20884971 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlong HAC stem
Number of subjects: 43
Study 20884971 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlong Active stem
Number of subjects: 43
Study 20884971 — intervention group
Group type: COMPARATOR
Intervention: Both stems
Number of subjects: 43
Study 17341661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory postremission strategy (6 consolidation cycles administered monthly in outpatients)
Number of subjects: 416
Study 17341661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory postremission strategy
Number of subjects: 416
Study 17341661 — intervention group
Group type: COMPARATOR
Intervention: Intensive strategy (single intensive consolidation course similar to induction)
Number of subjects: 416
Study 15625656 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (400 IU/day)
Number of subjects: 20
Study 15625656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day) and pioglitazone (30 mg/day)
Number of subjects: 20
Study 11171891 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen plus air blanket therapy (n = 113)
Number of subjects: 220
Study 11171891 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen alone (n = 107)
Number of subjects: 220
Study 9543597 — intervention group
Group type: EXPERIMENTAL
Intervention: mibefradil
Number of subjects: 143
Study 9543597 — intervention group
Group type: COMPARATOR
Intervention: nifedipine SR
Number of subjects: 143
Study 7851271 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion to inhibit tubular reabsorption (TR) of transferrin
Number of subjects: 64
Study 7851271 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 64
Study 7851271 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with microtransferrinuria
Number of subjects: 64
Study 7851271 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with normal TfER
Number of subjects: 64
Study 3133714 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 45
Study 3133714 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 45
Study 30801388 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screws
Number of subjects: 0
Study 30801388 — intervention group
Group type: COMPARATOR
Intervention: Cancellous screws
Number of subjects: 0
Study 30801388 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 28671553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (LVD)
Number of subjects: 17
Study 28671553 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 17
Study 28671553 — intervention group
Group type: EXPERIMENTAL
Intervention: High HBV viral load (>6 log IU/ml) patients in LVD group
Number of subjects: 17